Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

Merck KGaA

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Merck KGaA's 2013 sales performance.

Merck KGaA

Vyriad inks immunotherapy alliance with Merck/Pfizer

Vyriad inks immunotherapy alliance with Merck/Pfizer Genetically engineered virus produces immune response in tumours. Merck KGaA and its avelumab partner Pfizer have agreed to test the cancer immunotherapy alongside an oncolytic virus therapy developed by US biotech ... reach the market after

Communiqué: big wins for obesity and sugar tax campaigners

Communiqué: big wins for obesity and sugar tax campaigners The Lucid Group Award for Excellence in Corporate Social Responsibility. Merck KGaA’s ten year anniversary of its medicine donation programme in developing nations was also highlighted at the Awards, after ... For ten years, Merck has been donating the

Digging deeper to connect with the powerful force of patient understanding

Digging deeper to connect with the powerful force of patient understanding Holistic and connected. Mr Trautmann, Director, Global Data &Knowledge Management at Merck KGaA, insists market research can enable industry to gain that deeper understanding of the holistic elements of any condition

Immuno-oncology at ASCO: survival data, combinations and new indications

Immuno-oncology at ASCO: survival data, combinations and new indications Meanwhile, companies following after BMS and Merck, such as Roche, AZ and Merck KGaA/Pfizer, are also trying to carve out territory for their new drugs, and will be showcasing their ... The Merck/Pfizer partners are highlighting long-term data for PD-L1

Daily Brief: Azar blasts pharma, NICE forces MS drug prices down, Xenicos gets $30m funding

Daily Brief: Azar blasts pharma, NICE forces MS drug prices down, Xenicos gets $30m funding Teva’s Copaxone, Biogen’s Avonex and Merck Serono’s Rebif have all been accepted for routine use on the NHS after the companies agreed to lower their prices – in addition

[ Previous 5 results ] 8 9 10 11 12 13 14 15 16 17 [ Next 5 results ]

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Branding Science

We are Branding Science Partners in thinking which inspires change in healthcare Branding Science are an award-winning global pharmaceutical market...

Latest intelligence

Diversity in clinical trials: looking back at our 2021 blogs
In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
Webinar:
Securing a future for telehealth with immersive market research insights...